Clinical trials: Antipsychotic Agents
Dementia
Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial
Background: Up to 90% of nursing home residents with dementia experience behavioural and psychological symptoms like apathy, agitation, and anxiety.
- Trial name
- EPCentCare (NCT02295462)
- Testing
- Person-centered Care, Optimised Treatment
- Where
- 3 sites in Germany
- Volunteers
- 1,158 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Schizophrenia
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626859
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Tanabe Pharma Corporation
Behavioral and Psychiatric Symptoms of Dementia, Insomnia
Implementation of a Pharmacist-Driven Antipsychotic Deprescribing Initiative in the PACE Setting: A Pilot Study
The aim of this pilot study is to determine the feasibility of implementing an antipsychotic deprescribing initiative that is driven by pharmacists working collaboratively with the Program of All-inclusive Care for the Elderly…
- Trial name
- NCT04288193
- Testing
- Recommendation to Deprescribe
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants
The purpose of this study is to investigate the efficacy of flexibly dosed paliperidone extended-release (mechanism to dissolve a drug over time in order to be released slower and steadier into the blood stream) in improving or…
- Trial name
- PASS (NCT00761605)
- Testing
- Paliperidone
- Where
- 8 sites in South Korea
- Volunteers
- 387 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Schizophrenia, Bipolar Disorder
Effectiveness of Anti-Psychotic in GPs Setting
Evaluating the effectiveness of atypical antipsychotics in the community - a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium
- Trial name
- Serenity (NCT00543088)
- Where
- 57 sites in Belgium
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained…
- Trial name
- NCT00392743
- Testing
- pet/spect scan
- Where
- 7 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.
- Trial name
- NCT05741528
- Testing
- SEP-363856
- Where
- 16 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Conduct Disorder, fMRI
Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders
Background: Some children and teenagers have conditions known as conduct disorders. They often have long-term chronic behavior problems, such as defiant behavior or violence.
- Trial name
- NCT01867398
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Long-term Study of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
- Trial name
- NCT01104792
- Testing
- Cariprazine
- Where
- 86 sites in United States, Colombia and 4 more
- Volunteers
- 752 people
- Sponsor
- Forest Laboratories
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Functional Dyspepsia
Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia
The goal of this clinical trial is to assess and compare the effect of amitriptyline and trifluoperazine in improving dyspeptic symptoms in patients with functional dyspepsia.
- Trial name
- NCT07008235
- Testing
- Tablet Amitriptyline 10 milligrams, Tablet Trifluoperazine 1 milligrams twice daily, Standard First-Line Therapy
- Where
- Bangladesh
- Volunteers
- 120 people
- Sponsor
- Md. Moktadirul Hoque Shuvo
Insulin Resistance, Diabetes Mellitus
A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers
The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers.
- Trial name
- NCT00741026
- Testing
- Olanzapine 10 mg po qhs for 3 days
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Volunteers on Chronic, Stable Antipsychotic Regimens
Staccato Loxapine Multidose PK
The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.
- Trial name
- NCT00555412
- Testing
- A - 10 mg loxapine q 4 h x 3 (30 mg total), B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total), C - 5 mg loxapine q 4 h x 3 (15 mg total)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor, fluvoxamine, in healthy participants.
- Trial name
- NCT05712265
- Testing
- Miricorilant, Fluvoxamine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Bipolar Depression
What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression?
PURPOSE The purpose of this study is to elucidate whether quetiapine fumurate (Seroquel) exerts its antidepressant activity in bipolar disorder through altering either serotonergic or catecholinergic activity.
- Trial name
- NCT00817323
- Testing
- Dietary amino-acid depletion
- Sponsor
- University of British Columbia
Schizophrenia
Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive…
- Trial name
- OBSERVSPEECH (NCT06613334)
- Testing
- Blood test: measurement of plasma antipsychotic concentration, Voice interviews and questionnaires carried out via the CALLYOPE application
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier St Anne
Autism
Aripiprazole in Children With Autism: A Pilot Study
This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism. Children who qualify for the study will be treated with aripiprazole for 6 weeks.
- Trial name
- NCT00208533
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Drexel University College of Medicine